Sodium-glucose co-transporter-2 (SGLT2) inhibitors slow kidney disease progression and reduce cardiovascular risk in patients with CKD. Frailty is a state of increased vulnerability due to agingrelated decline in physiological reserve and is common in CKD. Without randomized evidence, perceived altered risk-benefit profile may lead to under-treatment of frail patients. We sought to derive a frailty indicator and use it to assess the risk-benefit profile of empagliflozin in CKD according to levels of frailty in EMPA-KIDNEY.
No takes yet. Share an insight, caveat, or question.
Kaitlin J. Mayne (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: